Diagnostic performance of plasma p‐tau217 and Aβ42/40 biomarkers in the outpatient memory clinic

Abstract

Plasma phosphorylated tau217 (p-tau217) reliably identified clinic patients with Alzheimer's disease. A two-cutpoint strategy yielded definitive results in 86% of patients. Integration of plasma amyloid beta (Aβ; p-tau217/Aβ42) minimally improved diagnostic performance. Plasma p-tau217 levels were increased in patients with kidney dysfunction.